Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Neuropharmacology
  4. Fast Track Articles
  5. Fast Track Article
image of Oral and Long-acting Injectable Aripiprazole in Severe Mental Illness and Substance Use Disorder Comorbidity: An Updated Systematic Review

Abstract

Background

Co-occurrence of substance use disorders is frequent in patients with mental health disorders is a condition known as “dual diagnosis”. The use of substances worsens the prognosis and lowers the quality of life of psychiatric patients. It also increases the risk of hospitalization and suicide rate.

Objectives

To assess the effects of aripiprazole therapy on substance use and other psychiatric outcomes in dually diagnosed patients.

Methods

We performed a systematic review conducted on 3 databases PUBMED, SCOPUS, and Web of Science, selecting original studies and analyzing the impact of aripiprazole therapy on dually diagnosed patients. Six hundred and fifty-five articles were founded and, after removing duplicates (n = 274) and applying the exclusion criteria, 12 articles were included in our systematic review.

Results

12 studies were included, among which 6 were Randomized Controlled Trials. The Most frequent psychiatric diagnosis were schizoaffective disorders, schizophrenia, and bipolar disorders. Alcohol and cocaine use disorders were the most used substances. Eleven studies showed a clinical improvement after aripiprazole treatment. 8 studies evaluated craving and found a significant reduction after treatment with aripiprazole. No definitive conclusions can be drawn on substance usage and maintenance of abstinence.

Conclusion

The present findings suggest aripiprazole may be associated with reducing substance craving and improving depression, psychosis, and schizoaffective disorders in dually diagnosed patients.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cn/10.2174/1570159X23666241023115252
2024-10-24
2024-12-29

  • From This Site

    /content/journals/cn/10.2174/1570159X23666241023115252
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Khokhar J.Y. Dwiel L.L. Henricks A.M. Doucette W.T. Green A.I. The link between schizophrenia and substance use disorder: A unifying hypothesis. Schizophr. Res. 2018 194 78 85 10.1016/j.schres.2017.04.016 28416205
    [Google Scholar]
  2. Edward K.L. Robins A. Dual diagnosis, as described by those who experience the disorder: Using the Internet as a source of data. Int. J. Ment. Health Nurs. 2012 21 6 550 559 10.1111/j.1447‑0349.2012.00833.x 22830579
    [Google Scholar]
  3. Hunt G.E. Malhi G.S. Lai H.M.X. Cleary M. Prevalence of comorbid substance use in major depressive disorder in community and clinical settings, 1990-2019: Systematic re-view and meta-analysis. J. Affect. Disord. 2020 266 288 304 10.1016/j.jad.2020.01.141 32056890
    [Google Scholar]
  4. Sullivan L.E. Fiellin D.A. O’Connor P.G. The prevalence and impact of alcohol problems in major depression: A sys-tematic review. Am. J. Med. 2005 118 4 330 341 10.1016/j.amjmed.2005.01.007 15808128
    [Google Scholar]
  5. Blanco C. Alegría A.A. Liu S.M. Secades-Villa R. Sugaya L. Davies C. Nunes E.V. Differences among major depressive disorder with and without co-occurring substance use disorders and substance-induced depressive disorder: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. J. Clin. Psychiatry 2012 73 6 865 873 10.4088/JCP.10m06673 22480900
    [Google Scholar]
  6. Vorspan F. Mehtelli W. Dupuy G. Bloch V. Lépine J.P. Anxiety and substance use disorders: Co-occurrence and clin-ical issues. Curr. Psychiatry Rep. 2015 17 2 4 10.1007/s11920‑014‑0544‑y 25617040
    [Google Scholar]
  7. Clay S. Allen J. Parran T. A review of addiction. Postgrad. Med. 2008 120 2 E01 E07 10.3810/pgm.2008.07.1802 18654058
    [Google Scholar]
  8. Jones C.A. Watson D.J.G. Fone K.C.F. Animal models of schizophrenia. Br. J. Pharmacol. 2011 164 4 1162 1194 10.1111/j.1476‑5381.2011.01386.x 21449915
    [Google Scholar]
  9. Trost S. Diekhof E.K. Zvonik K. Lewandowski M. Ush-er J. Keil M. Zilles D. Falkai P. Dechent P. Gruber O. Disturbed anterior prefrontal control of the mesolimbic re-ward system and increased impulsivity in bipolar disorder. Neuropsychopharmacology 2014 39 8 1914 1923 10.1038/npp.2014.39 24535101
    [Google Scholar]
  10. Spano M.C. Lorusso M. Pettorruso M. Zoratto F. Di Giuda D. Martinotti G. Giannantonio M. Anhedonia across borders: Transdiagnostic relevance of reward dysfunction for noninvasive brain stimulation endophenotypes. CNS Neurosci. Ther. 2019 25 11 1229 1236 10.1111/cns.13230 31638332
    [Google Scholar]
  11. Murthy P. Chand P. Treatment of dual diagnosis disorders. Curr. Opin. Psychiatry 2012 25 3 194 200 10.1097/YCO.0b013e328351a3e0 22395768
    [Google Scholar]
  12. Stahl S.M. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, “Goldilocks” actions at dopamine receptors. J. Clin. Psychiatry 2001 62 11 841 842 10.4088/JCP.v62n1101 11775041
    [Google Scholar]
  13. Jordan S. Koprivica V. Chen R. Tottori K. Kikuchi T. Altar C.A. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur. J. Pharmacol. 2002 441 3 137 140 10.1016/S0014‑2999(02)01532‑7 12063084
    [Google Scholar]
  14. Casey A.B. Canal C.E. Classics in chemical neuroscience. Aripiprazole. ACS Chem. Neurosci. 2017 8 6 1135 1146 10.1021/acschemneuro.7b00087 28368577
    [Google Scholar]
  15. Ribeiro E.L.A. de Mendonça Lima T. Vieira M.E.B. Stor-pirtis S. Aguiar P.M. Efficacy and safety of aripiprazole for the treatment of schizophrenia: An overview of systematic re-views. Eur. J. Clin. Pharmacol. 2018 74 10 1215 1233 10.1007/s00228‑018‑2498‑1 29905899
    [Google Scholar]
  16. Yatham L.N. Kennedy S.H. Parikh S.V. Schaffer A. Bond D.J. Frey B.N. Sharma V. Goldstein B.I. Rej S. Beaulieu S. Alda M. MacQueen G. Milev R.V. Ravin-dran A. O’Donovan C. McIntosh D. Lam R.W. Vazquez G. Kapczinski F. McIntyre R.S. Kozicky J. Kanba S. La-fer B. Suppes T. Calabrese J.R. Vieta E. Malhi G. Post R.M. Berk M. Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) 2018 guidelines for the management of pa-tients with bipolar disorder. Bipolar Disord. 2018 20 2 97 170 10.1111/bdi.12609 29536616
    [Google Scholar]
  17. Wobrock T. Soyka M. Pharmacotherapy of schizophrenia with comorbid substance use disorder — Reviewing the evi-dence and clinical recommendations. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008 32 6 1375 1385 10.1016/j.pnpbp.2008.02.008 18394768
    [Google Scholar]
  18. Wolf M.E. Synaptic mechanisms underlying persistent co-caine craving. Nat. Rev. Neurosci. 2016 17 6 351 365 10.1038/nrn.2016.39 27150400
    [Google Scholar]
  19. Martinotti G. De Risio L. Vannini C. Schifano F. Pettor-ruso M. Di Giannantonio M. Substance-related exogenous psychosis: A postmodern syndrome. CNS Spectr. 2021 26 1 84 91 10.1017/S1092852920001479 32580808
    [Google Scholar]
  20. Wang S. Historical review: Opiate addiction and opioid recep-tors. Cell Transplant. 2019 28 3 233 238 10.1177/0963689718811060 30419763
    [Google Scholar]
  21. Li X. Caprioli D. Marchant N.J. Recent updates on incuba-tion of drug craving: A mini-review. Addict. Biol. 2015 20 5 872 876 10.1111/adb.12205 25440081
    [Google Scholar]
  22. Kalivas P.W. Volkow N.D. The neural basis of addiction: A pathology of motivation and choice. Am. J. Psychiatry 2005 162 8 1403 1413 10.1176/appi.ajp.162.8.1403 16055761
    [Google Scholar]
  23. Grodin E.N. Courtney K.E. Ray L.A. Drug-induced crav-ing for methamphetamine is associated with neural metham-phetamine cue reactivity. J. Stud. Alcohol Drugs 2019 80 2 245 251 10.15288/jsad.2019.80.245 31014470
    [Google Scholar]
  24. Volkow N.D. Boyle M. Neuroscience of addiction: Rele-vance to prevention and treatment. Am. J. Psychiatry 2018 175 8 729 740 10.1176/appi.ajp.2018.17101174 29690790
    [Google Scholar]
  25. Pribiag H. Shin S. Wang E.H.J. Sun F. Datta P. Okamo-to A. Guss H. Jain A. Wang X.Y. De Freitas B. Honma P. Pate S. Lilascharoen V. Li Y. Lim B.K. Ventral pal-lidum DRD3 potentiates a pallido-habenular circuit driving accumbal dopamine release and cocaine seeking. Neuron 2021 109 13 2165 2182.e10 10.1016/j.neuron.2021.05.002 34048697
    [Google Scholar]
  26. Beresford T. Buchanan J. Thumm E.B. Emrick C. Weit-zenkamp D. Ronan P.J. Late reduction of cocaine cravings in a randomized, double-blind trial of aripiprazole vs per-phenazine in schizophrenia and comorbid cocaine depend-ence. J. Clin. Psychopharmacol. 2017 37 6 657 663 10.1097/JCP.0000000000000789 28984746
    [Google Scholar]
  27. Cuomo I. Kotzalidis G.D. de Persis S. Piacentino D. Perrini F. Amici E. De Filippis S. Head-to-head compari-son of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: Impact on clinical status, substance craving, and quality of life. Neuropsychiatr. Dis. Treat. 2018 14 1645 1656 10.2147/NDT.S171002 29950846
    [Google Scholar]
  28. Farnia V. Shakeri J. Tatari F. Juibari T.A. Yazdchi K. Bajoghli H. Brand S. Abdoli N. Aghaei A. Randomized controlled trial of aripiprazole versus risperidone for the treatment of amphetamine-induced psychosis. Am. J. Drug Alcohol Abuse 2014 40 1 10 15 10.3109/00952990.2013.861843 24359506
    [Google Scholar]
  29. Hyun Han D. Mi Kim S. Eun Choi J. Joon Min K. Ren-shawm P.F. Adjunctive aripiprazole therapy with escital-opram in patients with co-morbid major depressive disorder and alcohol dependence: Clinical and neuroimaging evidence Doug. Physiol. Behav. 2017 176 12 139 148 10.1177/0269881112472563.Adjunctive
    [Google Scholar]
  30. Sulaiman A.H. Gill J.S. Said M.A. Zainal N.Z. Hussein H.M. Guan N.C. A randomized, placebo-controlled trial of aripiprazole for the treatment of methamphetamine depend-ence and associated psychosis. Int. J. Psychiatry Clin. Pract. 2013 17 2 131 138 10.3109/13651501.2012.667116 22486597
    [Google Scholar]
  31. Skryabin V.Y. Vinnikova M.A. Ezhkova E.V. Titkov M.S. Bulatova R.A. Atypical antipsychotics in the treatment of patients with a dual diagnosis of schizophrenia spectrum disorders and substance use disorders: The results of a ran-domized comparative study. J. Addict. Dis. 2021 39 4 513 525 10.1080/10550887.2021.1905589 33832406
    [Google Scholar]
  32. Beresford T.P. Clapp L. Martin B. Wiberg J.L. Alfers J. Beresford H.F. Aripiprazole in schizophrenia with cocaine dependence: A pilot study. J. Clin. Psychopharmacol. 2005 25 4 363 366 10.1097/01.jcp.0000169419.38899.5b 16012280
    [Google Scholar]
  33. Bruno A. Romeo V.M. Pandolfo G. Scimeca G. Zoccali R.A. Muscatello M.R.A. Aripiprazole plus topiramate in opi-oid-dependent patients with schizoaffective disorder: An 8-week, open-label, uncontrolled, preliminary study. Subst. Abus. 2014 35 2 119 121 10.1080/08897077.2013.814615 24821345
    [Google Scholar]
  34. McRae-Clark A.L. Verduin M.L. Tolliver B.K. Carter R.E. Wahlquist A.E. Brady K.T. Cluver J.S. Anderson S. An open-label trial of aripiprazole treatment in dual diagnosis individuals: Safety and efficacy. J. Dual Diagn. 2009 5 1 83 96 10.1080/15504260802620210
    [Google Scholar]
  35. Brown E.S. Jeffress J. Liggin J.D.M. Garza M. Beard L. Switching outpatients with bipolar or schizoaffective disor-ders and substance abuse from their current antipsychotic to aripiprazole. J. Clin. Psychiatry 2005 66 6 756 760 10.4088/JCP.v66n0613 15960570
    [Google Scholar]
  36. Szerman N. Basurte-Villamor I. Vega P. Martinez-Raga J. Parro-Torres C. Cambra Almerge J. Grau-López L. De Matteis M. Arias F. Once-monthly long-acting injectable ar-ipiprazole for the treatment of patients with schizophrenia and co-occurring substance use disorders: A multicentre, observa-tional study. Drugs Real World Outcomes 2020 7 1 75 83 10.1007/s40801‑020‑00178‑8 32026379
    [Google Scholar]
  37. Martinotti G. Nicola M.D. Janiri L. Efficacy and safety of aripiprazole in alcohol dependence. Am. J. Drug Alcohol Abuse 2007 33 3 393 401 10.1080/00952990701313660 17613966
    [Google Scholar]
  38. Han D.H. Kim S.M. Choi J.E. Min K.J. Renshaw P.F. Adjunctive aripiprazole therapy with escitalopram in patients with co-morbid major depressive disorder and alcohol de-pendence: Clinical and neuroimaging evidence. J. Psychopharmacol. 2013 27 3 282 291 10.1177/0269881112472563 23325372
    [Google Scholar]
  39. McRae-Clark A.L. Efficacy and safety of aripiprazole in alcohol dependence. Drugs Real World Outcomes 2020 7 1 83 96 10.2147/NDT.S171002
    [Google Scholar]
  40. Sinha R. The clinical neurobiology of drug craving. Curr. Opin. Neurobiol. 2013 23 4 649 654 10.1016/j.conb.2013.05.001 23764204
    [Google Scholar]
  41. Koob G.F. Le Moal M. Se V. Neurobiological mechanisms for opponent motivational processes in addiction. 2008 3113 3123 10.1098/rstb.2008.0094
    [Google Scholar]
  42. Caine S.B. Negus S.S. Mello N.K. Patel S. Bristow L. Kulagowski J. Vallone D. Saiardi A. Borrelli E. Role of dopamine D2-like receptors in cocaine self-administration: Studies with D2 receptor mutant mice and novel D2 receptor antagonists. J. Neurosci. 2002 22 7 2977 2988 10.1523/JNEUROSCI.22‑07‑02977.2002 11923462
    [Google Scholar]
  43. Miuli A. Pettorruso M. Romanelli E. Stigliano G. Di Giuda D. De-Giorgio F. Martinotti G. di Giannantonio M. Does DRD2 Taq1A mediate aripiprazole-induced gambling disorder? a pharmacogenetic hypothesis. Front. Psychiatry 2020 11 275 10.3389/fpsyt.2020.00275 32351415
    [Google Scholar]
  44. Vorel S.R. Ashby C.R. Jr Paul M. Liu X. Hayes R. Hagan J.J. Middlemiss D.N. Stemp G. Gardner E.L. Do-pamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J. Neurosci. 2002 22 21 9595 9603 10.1523/JNEUROSCI.22‑21‑09595.2002 12417684
    [Google Scholar]
  45. Wolfschlag M. Håkansson A. Increased risk for developing gambling disorder under the treatment with pramipexole, ropinirole, and aripiprazole: A nationwide register study in Sweden. PLoS One 2021 16 6 e0252516 10.1371/journal.pone.0252516 34061895
    [Google Scholar]
  46. Pettorruso M. Zoratto F. Miuli A. De Risio L. Santorelli M. Pierotti A. Martinotti G. Adriani W. di Giannantonio M. Exploring dopaminergic transmission in gambling addic-tion: A systematic translational review. Neurosci. Biobehav. Rev. 2020 119 481 511 10.1016/j.neubiorev.2020.09.034 33035523
    [Google Scholar]
  47. Correll C.U. The use of long-acting injectable antipsychotics in schizophrenia: Evaluating the evidence. J. Clin. Psychiatry 2016 77 Suppl. 3 1 24 10.4088/JCP.15032su1
    [Google Scholar]
  48. Misawa F. Kishimoto T. Hagi K. Kane J.M. Correll C.U. Safety and tolerability of long-acting injectable versus oral an-tipsychotics: A meta-analysis of randomized controlled stud-ies comparing the same antipsychotics. Schizophr. Res. 2016 176 2-3 220 230 10.1016/j.schres.2016.07.018 27499361
    [Google Scholar]
  49. Coles A.S. Knezevic D. George T.P. Correll C.U. Kane J.M. Castle D. Long-acting injectable antipsychotic treatment in schizophrenia and co-occurring substance use disorders: A systematic review. Front. Psychiatry 2021 12 808002 10.3389/fpsyt.2021.808002 34975600
    [Google Scholar]
/content/journals/cn/10.2174/1570159X23666241023115252
Loading
Oral and Long-acting Injectable Aripiprazole in Severe Mental Illness and Substance Use Disorder Comorbidity: An Updated Systematic Review
Bentham Science Publishers ; https://doi.org/10.2174/1570159X23666241023115252
/content/journals/cn/10.2174/1570159X23666241023115252
/content/journals/cn/10.2174/1570159X23666241023115252
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: dual disorder ; craving ; Schizophrenia ; substance use disorder ; aripiprazole ; bipolar disorder

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test